EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma
In conclusion, EASIX aids in risk stratification at clinically relevant time points prior to CAR T-cell therapy with ide-cel. Increased EASIX levels might help clinicians to identify vulnerable patients to adapt peri-CAR-T management at an early stage.
Authors
- Iris Breitkreutz (ORCID: https://orcid.org/0000-0002-6038-2755)
- Xiang Zhou (ORCID: https://orcid.org/0000-0003-3885-0919)
- Hermann Einsele (ORCID: https://orcid.org/0000-0002-7680-0819)
- Michael Schmitt (ORCID: https://orcid.org/0000-0002-1579-1509)
- Leo Rasche (ORCID: https://orcid.org/0000-0002-9536-9649)
- Carsten Müller‐Tidow (ORCID: https://orcid.org/0000-0002-7166-5232)
- Marina Hajiyianni
- Patrick Costello (ORCID: https://orcid.org/0009-0008-2565-1092)
- Jan Frenking (ORCID: https://orcid.org/0009-0001-9682-2601)
- Nikhil C. Munshi (ORCID: https://orcid.org/0000-0002-7344-9795)
- Omar Nadeem (ORCID: https://orcid.org/0000-0002-4124-4277)
- Christian Michel (ORCID: https://orcid.org/0009-0004-1596-3763)
- Niels Weinhold (ORCID: https://orcid.org/0000-0002-5464-3234)
- Joseph Kauer (ORCID: https://orcid.org/0000-0003-1632-0167)
- Hartmut Goldschmidt (ORCID: https://orcid.org/0000-0003-0961-0035)
- Thomas Luft (ORCID: https://orcid.org/0000-0002-0387-1640)
- Marc S. Raab (ORCID: https://orcid.org/0000-0003-4181-6922)
- Adam S. Sperling (ORCID: https://orcid.org/0000-0002-9369-4413)
- Sandra Sauer (ORCID: https://orcid.org/0000-0001-5552-3149)
- Mirco Friedrich (ORCID: https://orcid.org/0000-0002-6401-3623)
- Peter Dreger (ORCID: https://orcid.org/0000-0002-7429-8570)
- Thomas Hielscher (ORCID: https://orcid.org/0000-0003-1277-310X)
- Max S. Topp (ORCID: https://orcid.org/0000-0002-1267-5289)
- V. Wagner
- Anita Schmitt
- K. Elias (ORCID: https://orcid.org/0000-0002-6226-1252)
Institutions
- Broad Institute (US)
- Brigham and Women's Hospital (US)
- German Cancer Research Center (DE)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- National Center for Tumor Diseases (DE)
- Dana-Farber Cancer Institute (US)
- Universitätsklinikum Würzburg (DE)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1136/jitc-2024-009220
- Citations
- 28
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 7.91
Funders
- U.S. Department of Defense
- Amgen
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Celgene
- Therakos
- Regeneron Pharmaceuticals
- Jazz Pharmaceuticals
- Les Laboratories Pierre Fabre
- BeiGene
- Incyte
- SkylineDx
- Deutsche Forschungsgemeinschaft
- Interdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum Würzburg
- National Cancer Institute
- Cilag